CLINICAL TRIALS PROFILE FOR LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

All Clinical Trials for Levaquin In Dextrose 5% In Plastic Container

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00035347 ↗	Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia	Completed	Pfizer	Phase 4	2001-01-01	A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens. After written informed consent is obtained, patients will receive one of the following two treatment regimens: 1) intravenous administration of azithromycin and ceftriaxone followed by azithromycin tablets, or 2) intravenous administration of levofloxacin followed by levofloxacin tablets. At least four study visits are normally conducted up to approximately one month after starting therapy. The objective of this study is to compare the safety and efficacy of the two treatment regimens.
NCT00176306 ↗	Levofloxacin Pharmacokinetics (PK) in the Severely Obese	Completed	Ortho-McNeil Pharmaceutical	Phase 4	2005-01-01	Obesity is known to affect the concentrations of certain medications in the body. Levofloxacin is a commonly used antibiotic. Based on what the investigators know about levofloxacin and how it moves through the body, obesity may affect levofloxacin concentrations. This study aims to show the effect of obesity on levofloxacin concentrations. The hypothesis is as follows: A 750 mg intravenous (IV) dose of levofloxacin administered to severely obese, critically ill patients will yield serum concentrations that are likely to be therapeutic.
NCT00176306 ↗	Levofloxacin Pharmacokinetics (PK) in the Severely Obese	Completed	Joel Thompson, PhD	Phase 4	2005-01-01	Obesity is known to affect the concentrations of certain medications in the body. Levofloxacin is a commonly used antibiotic. Based on what the investigators know about levofloxacin and how it moves through the body, obesity may affect levofloxacin concentrations. This study aims to show the effect of obesity on levofloxacin concentrations. The hypothesis is as follows: A 750 mg intravenous (IV) dose of levofloxacin administered to severely obese, critically ill patients will yield serum concentrations that are likely to be therapeutic.
NCT00176306 ↗	Levofloxacin Pharmacokinetics (PK) in the Severely Obese	Completed	University of Kentucky	Phase 4	2005-01-01	Obesity is known to affect the concentrations of certain medications in the body. Levofloxacin is a commonly used antibiotic. Based on what the investigators know about levofloxacin and how it moves through the body, obesity may affect levofloxacin concentrations. This study aims to show the effect of obesity on levofloxacin concentrations. The hypothesis is as follows: A 750 mg intravenous (IV) dose of levofloxacin administered to severely obese, critically ill patients will yield serum concentrations that are likely to be therapeutic.
NCT00250718 ↗	Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach	Terminated	New Mexico Cancer Care Alliance	Phase 2	2004-10-01	1.1 To determine the efficacy of a combination treatment of VP-16, chlorambucil, dexamethasone, and vincristine in patients with relapsed/refractory hematological malignancies. 1.2 To determine the toxicity profile of the above regimen in this patient population. 1.3 Evaluate the effect of low dose administration of chemotherapy on angiogenesis, and correlate this with tumor responses.

Clinical Trial Conditions for Levaquin In Dextrose 5% In Plastic Container

Condition Name

Condition Name for Levaquin In Dextrose 5% In Plastic Container
Intervention	Trials
Pneumonia, Bacterial	1
BK Viremia	1
Urinary Tract Infection	1
Community-Acquired Bacterial Pneumonia	1

Condition MeSH

Condition MeSH for Levaquin In Dextrose 5% In Plastic Container
Intervention	Trials
Tuberculosis	4
Infections	4
Infection	4
Pneumonia	4

Clinical Trial Locations for Levaquin In Dextrose 5% In Plastic Container

Trials by Country

Trials by Country for Levaquin In Dextrose 5% In Plastic Container
Location	Trials
United States	127
Canada	13
Georgia	4
Moldova, Republic of	3
Russian Federation	3

Trials by US State

Trials by US State for Levaquin In Dextrose 5% In Plastic Container
Location	Trials
Florida	7
California	7
Texas	6
Ohio	6
New York	6

Clinical Trial Progress for Levaquin In Dextrose 5% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Levaquin In Dextrose 5% In Plastic Container
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	6
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Levaquin In Dextrose 5% In Plastic Container
Clinical Trial Phase	Trials
Completed	15
Terminated	3
Unknown status	2

Clinical Trial Sponsors for Levaquin In Dextrose 5% In Plastic Container

Sponsor Name

Sponsor Name for Levaquin In Dextrose 5% In Plastic Container
Sponsor	Trials
Tetraphase Pharmaceuticals, Inc.	2
Pfizer	2
Westat	2

Sponsor Type

Sponsor Type for Levaquin In Dextrose 5% In Plastic Container
Sponsor	Trials
Other	33
Industry	16
NIH	5